Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine in Relapsed/Refractory DLBCL
NCT03589469Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by ADC Therapeutics. Started Aug 2018; status: completed.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03589469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589469.